Pharmacokinetic Study of DYANAVEL XR (Amphetamine) Extended-release Oral Suspension, in Children Aged 4 to 5 Years

Condition:   Attention Deficit Hyperactivity Disorder Intervention:   Drug: Amphetamine Extended Release Suspension [Dyanavel] Sponsor:   Tris Pharma, Inc. Completed
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials